{
    "title": "114_hr2338",
    "content": "This bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration (FDA) to establish processes under which: (1) an entity seeking to develop patient experience data may submit initial research concepts for feedback. (2) the FDA may request or receive from such an entity draft guidance documents, data, and summaries and analyses of data. And (3) patient experience data may be considered in the risk-benefit assessment of a new drug. ldquo, Patient experience datardquo. Is data collected by patients or others that is intended to facilitate the FDA's risk-benefit assessments, including information about the impact of a disease or a therapy on patients' lives. The FDA must convene workshops and publish guidance on the patient experience data processes described above."
}